Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women

Maturitas

Volumn 50, Issue 3, 2005, Pages 182-188

  Kaya, Hakan ^a   Ozkaya, Okan ^a   Sezik, Mekin ^a   Arslanoglu, Evrim ^a   Yilmaztepe, Arzu ^b   Ulukaya, Engin ^b  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Antioxidant; Glutathione peroxidase; Malondialdehyde; Raloxifene; Superoxide dismutase

Indexed keywords

GLUTATHIONE PEROXIDASE; MALONALDEHYDE; RALOXIFENE; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; INTERMETHOD COMPARISON; NORMAL HUMAN; POSTMENOPAUSE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 13944274553     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.05.005     Document Type: Article

References (22)

1. Wenger N.K., Speroff L., Packard B. Cardiovascular health and disease in women. N. Engl. J. Med. 329:1993;247-256
2. Barrett-Connor E., Bush T.L. Estrogen and coronary heart disease in women. J. Am. Med. Assoc. 265:1991;1861-1867
3. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20:1991;47-63
4. Colditz G.A., Hankinson S.E., Hunter D.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332:1995;1589-1593
5. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J. Am. Med. Assoc. 280:1998;605-613
6. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N. Eng. J. Med. 343:2000;522-529
7. Mitlak B.H., Cohen F.J. Selective estrogen receptor modulators: a look ahead. Drugs. 57:1999;653-663
8. Walsh B.W., Kuller L.H., Wild R.A., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J. Am. Med. Assoc. 279:1998;1445-1451
9. Arteaga E., Villaseca P., Bianchi M., Rojas A., Marshall G. Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifene in postmenopausal women in vitro. Menopause. 10:2003;142-146
10. Wassmann S., Laufs U., Stamenkovic D., et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation. 105:2002;2083-2091
11. Simoncini T., Genazzani A.R., Liao J.K. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation. 105:2002;1368-1373
12. Rahimian R., Dube G.P., Toma W., Dos Santos N., McManus B.M., Breemen van C. Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur. J. Pharmacol. 434:2002;141-149
13. Pavo I., Laszlo F., Morschl E., et al. Raloxifene, an oestrogen-receptor modulator, prevents decreased constitutive nitric oxide and vasoconstriction in ovariectimized rats. Eur. J. Pharmacol. 410:2000;101-104
14. Ozgonul M., Oge A., Sezer E.D., Bayraktar F., Sozmen E.Y. The effects of estrogen and raloxifene treatment on antioxidant enzymes in brain and liver of ovariectomized female rats. Endocr. Res. 29:2003;183-189
15. Colacurci N., Manzella D., Fornaro F., Carbonella M., Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J. Clin. Endocrinol. Metab. 88:2003;2135-2140
16. Kampen van E.J., Zijlastra W.G. Standardization of hemoglobinometry. II. The hemiglobincyanide method. Clin. Chim. Acta. 6:1961;538-544
17. International committee for standardization in haemotology. Recommendations for haemoglobinometry in human blood, Br J Haematol 1967;13:71-5.
18. Kamal A., Gomaa A., Khafif M., Hammad A. Plasma lipid peroxides among workers exposed to silica or asbestos dusts. Environ. Res. 49:1989;173-180
19. Quinn M.T., Parthasarathy S., Fong L.G., Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. U.S.A. 84:1987;2995-2998
20. Lacort M., Leal A.M., Liza M., Martin C., Martinez R., Ruiz-Larrea M.B. Protective effect of estrogens and catecholestrogens against peroxidative membrane damage in vitro. Lipids. 30:1995;141-146
21. Zuckerman S.H., Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis. 126:1996;65-75
22. Oge A., Sezer E.D., Ozgonul M., Bayraktar F., Sozmen E.Y. The effects of estrogen and raloxifene treatment on the antioxidant enzymes and nitrite-nitrate levels in brain cortex of ovariectomized rats. Neurosci. Lett. 338:2003;217-220